79 results about "Immunoglobulin E" patented technology

Embodiments of the invention provide shaped masses (SM) comprising one or more drugs such as proteins or polypeptides and methods for forming and delivering such SM's. One embodiment provides a SM comprising a drug e.g., a protein or polypeptide having a biological activity in the body of a mammal. The SM is formed by compression of a precursor material (PM) comprising the drug wherein an amount of biologically active drug in the SM is a minimum level to that in the PM. Drugs which may be incorporated into the SM include insulin, incretins and immunoglobulins e.g., interleukin neutralizing antibodies or TNF-α-inhibiting antibodies. Embodiments of the invention are particularly useful for the oral delivery of drugs which would be degraded within the GI tract, wherein the SM containing the drug is formed as or incorporated into a tissue penetrating member which is inserted into the intestinal wall after oral ingestion.

The invention discloses adapter modified nano silver. A nano silver ball with the diameter of 10nm to 30nm is used as a kernel; and the outer surface of the silver ball is bonded with an adapter chain and an oligonucleotide chain. The invention also discloses a preparation method of the adapter modified nano silver, a reagent kit comprising the adapter modified nano silver, and application of the adapter modified nano silver to preparation of a reagent for detecting IgE (Immunoglobulin E). When used for carrying out the detection of IgE, the nano silver material provided by the invention has high sensitivity, short detection time (about 2h to 3h), simple and feasible operation and visual detection result; downhole semi-quantitative detection can be achieved in a visual mode without the need of an especially expensive detection apparatus; and the adapter modified nano silver has low cost, can realize bulk detection, and is suitable for popularization and utilization.

The invention relates to the field of medicines, and in particular to compound probiotic, application thereof for treating anaphylactic diseases and allergy free probiotic electuary for pregnant and lying-in women. The compound probiotic consists of bifidobacterium Bi-07, lactobacillus rhamnosus LR22, lactobacillus acidophilus NCFM. The compound probiotic not only can irritate secretion of IFN-gamma and IL-2 in animal body, but also inhibit secretion of immune globulin E (IgE) and IL-4 so as to prevent and treat anaphylactic diseases. The invention further provides a medical preparation comprising the compound probiotic and allergy free probiotic electuary for pregnant and lying-in women. The pharmacodynamic test shows that the medical preparation has remarkable effect of improving IL-2 and IFN-gamma. In addition, compared with the control group, the content of IgE in the test group is further remarkably reduced. Long-term clinical tests show that the medical preparation comprising the compound probiotic provided by the invention is free from untoward effects to human body.

The present invention discloses methods for immunizing against autologous (self) Immunoglobulin E (IgE). In particular, the invention discloses methods for inducing cytotoxic T-lymphocytes that will specifically down-regulate B-cells producing autologous IgE, notably by means of nucleic acid vaccination or live vaccination. Also disclosed are methods for inducing antibodies reactive with autologous IgE as well as methods for inducing a combined antibody and CTK response specific for IgE. The invention also discloses specific immunogenic protein constructs, nucleic acids encoding these as well as various formulations and tools for preparing the vaccines, including vectors and transformed host cells.

The invention discloses an immunoglobulin E immunoturbidimetry detection kit, and belongs to the technical field of clinical in-vitro detection reagents. The kit comprises a reagent R1, a reagent R2, and a calibration material. By adding a certain amount of silica coated magnetic nanoparticles into the reagent R1 and adding a certain amount of bovine serum albumin and Kathon-CG into the reagent R2, the stability and the analysis sensitivity of the kit are effectively improved, the linear range is also better, the reagent accuracy is high, and further popularization and application in markets are facilitated.

The invention discloses a marker and a primer for detecting pediatric asthma, belonging to the technical field of auxiliary diagnosis of pediatric asthma. According to the invention, the genotype of an SNP (single nucleotide polymorphisms) 290G / A site of a GATA3 gene 5' promoter region can be analyzed by adopting a PCR (Polymerase Chain Reaction) method through extracting the genomic DNA from the blood of children in an asthma group, and the relation between the 290G / A of the GATA3 gene and the Han-nationality pediatric asthma in Beijing of China is evaluated. The association research result indicates that the SNP290G / A of the GATA3 gene is associative to the pediatric asthma in Beijing area, is a high-risk factor of the pediatric asthma, and is higher in sensibility compared with the total IgE (immunoglobulin E) detected.

The invention relates to high affinity human monoclonal antibodies, particularly those directed against isotypic determinants of immunoglobulin E (IgE), as well as direct equivalents and derivatives of these antibodies. These antibodies bind to their respective target with an affinity at least 100 fold greater than the original parent antibody. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.

The present invention relates to an anti-atopic cream comprising: a first component comprising Houttuynia cordata, Acori gramineri Rhizoma, Saposhnikoviae Radix, Astragalus membranaceus Radix, Eriobotryae Folium, Sophorae flavescentis Radix, Saururus chinensis, Phellodendron bark, Centella asiatica, Arisaematis Rhizoma and Aster yomena; and a second component comprising glycerol, a caprylic or capric triglyceride, sunflower seed oil, butylene glycol, butylene glycol dicaprylate or dicaprate, macadamia seed oil, polyglyceryl-3 methylglucose distearate, PEG-4 olivate, meadowfoam seed oil, dimethicone, cetyl ethylhexanoate, oxidized corn oil, cetearyl alcohol, tocopheryl acetate, glyceryl acrylate or acrylic acid copolymer, stearyl glycyrrhetinate, sodium chloride, sodium acrylate or sodium acryloyl dimethyl taurate copolymer, algin, isohexadecane, caprylyl glycol, polysorbate 80, allantoin, caprylhydroxamic acid, propylene glycol, disodium EDTA and ceramide 3 and, in the anti-atopic cream, the first component and the second component are mixed in a weight ratio of between 5:5 and 7:3. According to the present invention, when the anti-atopic cream is applied to a DNCB induced atopic dermatitis mouse, the blood IgE is reduced and at the same time the amount of discharged histamine produced from the mast cells is suppressed, thereby making it possible to provide an anti-atopic cream having a therapeutic effect in atopic dermatitis.

Human saliva is used as a non-invasive source instead of invasive blood serum plasma for detection and assay of endogenously present proteins; nerve growth factor (NGF), myoglobin, Insulin, adenosine deaminase (ADA), including immunoglobulin E (IgE). It was discovered that people having high levels of IgE, show high levels in comparison to the normal controls of NGF, myoglobin, insulin and ADA, disrupting the homeostasis for these proteins. Oral administration of a synthetic peptide LT-10 disclosed in U.S. Pat. No. 5,576,297 having sequence L K A M D P T P P L reduces free IgE level in humans and brings other proteins int homeostasis, for example, NGF, myoglobin, insulin and ADA and possibly other proteins and cytokines. Composition of synthetic LT-10 is advocated as a treatment for IgE implicated disorders such as asthma, depression and various types of autoimmune diseases, such as erythematosus (SLE); Rheumatoid arthritis Sjogren's syndrome; Reiter's syndrome; Diabetes mellitus (insulin-dependent); Graves' disease; Addison's disease; Hodgkin's disease, etc.

Provided are methods for the detection and diagnosis of Hypothyroidism. The methods are based on the discovery that altered levels of selected analytes in sample fluid, typically blood samples, of patients are supportive of a diagnosis of Hypothyroidism. At least twenty-four new biomarkers for hypothyroidism are thus disclosed (singly or in any combination), Thyroid Stimulating Hormone, Interleukin-12p40, Tumor Necrosis Factor Alpha, Tissue Factor, Interleukin-15, Insulin, Immunoglobulin E, Growth Stimulating Hormone, Calcitonin, Prostate-Specific Antigen, Interleukin-4, Granulocyte Macrophage Colony Stimulating Factor, Matrix Metalloproteinase 9, Lymphotactin, Fatty Acid Binding Protein, Alpha Fetoprotein, Alpha-2 Macroglobulin, Serum Glutamic Oxaloacetic Transaminase, Matrix Metalloproteinase 3, Cancer Antigen 125, Mumps Antibody, Double Stranded DNA Antibody, Proliferating Cell Nuclear Antigen Antibody, Smith Antibody, or Herpes Simplex Virus 1 Glycoprotein D Antibody. Altogether the concentrations of one or more of these analytes, as well as Thyroid Stimulating Hormone, or any combination thereof, provide a sensitive and selective picture of the patient's condition, namely, whether the patient is suffering from Hypothyroidism. Kits containing reagents to assist in the analysis of fluid samples are also described.

The present invention provides antibodies (e.g., monoclonal antibodies) that specifically binds to mammalian IgE (e.g., dog IgE). In some embodiments the antibodies bind to an epitope between amino acids 145–166 of mammalian IgE; in other embodiments the antibodies bind to an epitope between amino acids 356–374 of mammalian IgE. The antibodies may be used for allergen reactivity testing in human subjects or animal subjects for veterinary purposes.

Human saliva is used as a non-invasive source instead of invasive blood serum plasma for detection and assay of endogenously present proteins; nerve growth factor (NGF), myoglobin, Insulin, adenosine deaminase (ADA), including immunoglobulin E (IgE). It was discovered that people having high levels of IgE, show high levels in comparison to the normal controls of NGF, myoglobin, insulin and ADA, disrupting the homeostasis for these proteins. Oral administration of a synthetic peptide LT-10 disclosed in U.S. Pat. No. 5,576,297 having sequence L K A M D P T P P L reduces IgE level in humans and bring other proteins into homeostasis, for example, NGF, myoglobin, insulin and ADA and possibly other proteins and cytokines. Composition of synthetic LT-10 is advocated as a treatment for IgE implicated disorders such as asthma, depression and various types of autoimmune diseases, such as erythematosus (SLE); Rheumatoid arthritis Sjogren's syndrome; Reiter's syndrome; Diabetes mellitus (insulin-dependent); Graves' disease; Addison's disease; Hodgkin's disease, etc.

The invention discloses a detection method which is high in sensitivity, fast and accurate and can rapidly measure human immunoglobulin E (hIg E). The method is realized by constructing a carbon nano tube micro-cantilever biosensor. The biosensor comprises a bracket, a substrate material, a carbon nano tube and a pick-up circuit, wherein an aptamer layer is modified on the carbon nano tube. The method comprises the following steps of: manufacturing a detection probe containing a hIg E aptamer on a carbon nano tube micro-cantilever, putting the detection probe into a sample to be detected during detection, forming a compound between the hIg E in the sample to be detected and the aptamer on the detection probe through a specific reaction and attaching the compound to the micro-cantilever; and detecting the hIg E by utilizing change relationship of deflection displacement or resonant frequency of the micro-cantilever caused by mass change of the compound generated on the micro-cantilever and positive correlation between the mass size of the compound and the concentration of the hIg E in the sample to be detected.

The invention discloses a steady humanized monoclonal antibody preparation, which comprises anti-IgE (immunoglobulin E) humanized monoclonal antibody, a protecting agent, a buffering agent, a surfactant, an isoosmotic adjusting agent, and the like. The composition disclosed by the invention has the advantages of stability and convenience for use.

The invention discloses a recombinant horse allergen and a mutant and preparation methods and applications thereof. The recombinant horse allergen is a non-natural mutant derived from a natural allergen, and the amino acid sequence of the recombinant horse allergen is shown as SEQ ID NO:1. An encoding gene of the recombinant horse allergen is artificially synthesized after codon optimization by using a gene engineering technology, the epitope of the encoding gene is analyzed by adopting bioinformatics software, and orientated displacement is performed specific to one or more high-antigenicity loci through a site-specific mutagenesis method to lower the allergenicity, so that a recombinant horse allergen mutant with low allergenicity is constructed. Protein expression is performed under an artificial control condition, so that a high-purity recombinant horse allergen and a mutant protein thereof are obtained. Compared with a natural horse allergen, the recombinant protein mutant has remarkably-lowered bonding capability with specific IgE (Immunoglobulin E), and can be safely applied to diagnosis and treatment of anaphylactic diseases and even judgment of the level of the allergenicity of other proteins.

The invention discloses aptamers capable of binding to Immunoglobulin E (“IgE”) useful as therapeutics in and diagnostics of atopic disease and / or other diseases or disorders in which IgE has been implicated. The invention further relates to materials and methods for the administration of aptamers capable of binding to IgE.

The present invention discloses methods for immunizing against autologous (self) Immunoglobulin E (IgE). In particular, the invention discloses methods for inducing cytotoxic T-lymphocytes that will specifically down-regulate B-cells producing autologous IgE, notably by means of nucleic acid vaccination or live vaccination. Also disclosed are methods for inducing antibodies reactive with autologous IgE as well as methods for inducing a combined antibody and CTK response specific for IgE. The invention also discloses specific immunogenic protein constructs, nucleic acids encoding these as well as various formulations and tools for preparing the vaccines, including vectors and transformed host cells.

The invention provides a test strip for screening specific animal fur and scurf allergens IgE (Immunoglobulin E). The test strip is coated with an animal fur and scurf antigen marked by colloidal gold. The test strip utilizes a colloidal gold marking technology; firstly, the colloidal gold mark is used for marking the specific animal fur and scurf allergens; then the marked allergens are uniformly sprayed on a cellulose acetate membrane or a nitrocellulose membrane to prepare a test strip product to carry out allergen detection; the test strip is simple and convenient to operate, accurate in result and low in cost and can realize multi-term free detection.

The invention discloses aptamers capable of binding to Immunoglobulin E (“IgE”) useful as therapeutics in and diagnostics of atopic disease and / or other diseases or disorders in which IgE has been implicated. The invention further relates to materials and methods for the administration of aptamers capable of binding to IgE.

The invention provides a test strip for screening specific spices allergens IgE (Immunoglobulin E). The test strip is coated with a spices antigen marked by colloidal gold. The test strip utilizes a colloidal gold marking technology; firstly, the colloidal gold mark is used for marking the specific spices allergens; then the marked allergens are uniformly sprayed on a cellulose acetate membrane or a nitrocellulose membrane to prepare a test strip product to carry out allergen detection; the test strip is simple and convenient to operate, accurate in result and low in cost and can realize multi-term free detection.

The invention provides a test strip for screening specific aquatic products allergens IgE (Immunoglobulin E). The test strip is coated with an aquatic products antigen marked by colloidal gold. The test strip utilizes a colloidal gold marking technology; firstly, the colloidal gold mark is used for marking the specific aquatic products allergens; then the marked allergens are uniformly sprayed on a cellulose acetate membrane or a nitrocellulose membrane to prepare a test strip product to carry out allergen detection; the test strip is simple and convenient to operate, accurate in result and low in cost and can realize multi-term free detection.

The invention discloses a method for identifying specific DNA sequences in germplasm resources based on surface plasma resonance technology, belonging to the technical field of germplasm resource identification. The method comprises four steps as the followings: fixing an aptamer on the surface of a sensing surface, marking a sample, identifying the sample, and regenerating a sensing element. The method utilizes the same sensing chip to identify different DNA sequences. The method is characterized by using immunoglobulin E as a marked molecular probe, and connecting the sensing chip surface with the immunoglobulin E aptamer; carrying out a series of pretreatment on a food sample, adding a single-stranded DNA immunoglobulin E marker, after mixing, competitively binding a corresponding aptamer of the single-stranded DNA modified by metal nano particles; detecting the content of immunoglobulin E by using a surface plasma resonance detector, indirectly identifying the specific single-stranded DNA sequences; and regenerating the sensing chip for detecting the other specific DNA sequences. The invention provides an effective identification method of specific DNA sequences in germplasm resources, thereby realizing the identification of different DNA sequences by the same surface plasma resonance sensing chip, and the method has extremely high versatility.

A method for detecting human immune globulin E with the concentration of 0.5-10[mu]g / mL is realized by constructing a carbon nanotube micro-cantilever biosensor. The biosensor comprises a support, a substrate material, a carbon nanotube and a pick-up circuit, and the carbon nanotube is modified with a layer of nucleic acid aptamers through a hydrophobic effect. The method comprises the following steps: a detection probe containing an hIgE nucleic acid aptamer is made on a carbon nanotube micro-cantilever, the detection probe is put in a sample to be detected during detection, hIgE in the sample to be detected and the nucleic acid aptamer on the detection probe form a compound and are attached to the micro-cantilever through a specific reaction; and a micro-cantilever deflection displacement or resonant frequency change caused by the mass change of the compound on the micro-cantilever is positively related to the concentration of hIgE in the sample to be detected in order to realize hIgE detection.

The invention discloses a kit and method for detecting STAT3 gene mutation of high IgE (Immunoglobulin E) syndrome. The kit comprises (i) a blood DNA (Deoxyribonucleic Acid) extraction reagent; (ii) PCR (Polymerase Chain Reaction) amplification reaction liquid for detecting a system; (iii) a reagent for sequencing the system; wherein primers comprise amplification primers and sequencing primers for amplifying whole exon sequences of STAT3 genes. In addition, a Sanger sequencing technology is used. According to the method disclosed by the invention, the mutation of whole exons of the STAT3 genes in the body of a patient with the high IgE syndrome can be quickly detected out. The detecting results obtained by through the invention can be used for assisting in diagnosis of the high IgE syndrome, which has an important reference significance for early intervention and early treatment.

The invention provides a test strip for screening specific tetanus antitoxin allergen IgE (Immunoglobulin E). The test strip is coated by a tetanus antitoxin antigen labeled by colloidal gold. The colloidal gold labelling technology is utilized in the invention; the specific tetanus antitoxin allergen is labelled by using colloidal gold for the first time; then, the labelled allergen is uniformly sprayed on a cellulose acetate membrane or a nitrocellulose membrane, therefore, the test strip is prepared for detecting allergens; the test strip disclosed by the invention is simple and convenient to operate, accurate in result and low in cost; and a number of free tests can be realized.

The invention provides a test strip for screening specific albumen allergens IgE (Immunoglobulin E). The test strip is coated with an albumen antigen marked by colloidal gold. The test strip utilizes a colloidal gold marking technology; firstly, the colloidal gold mark is used for marking the specific albumen allergens; then the marked allergens are uniformly sprayed on a cellulose acetate membrane or a nitrocellulose membrane to prepare a test strip product to carry out allergen detection; the test strip is simple and convenient to operate, accurate in result and low in cost and can realize multi-term free detection.

The invention discloses a fluorescent dye labeling aptamer for immune globulin E with sensitive fluorescence anisotropy (fluorescence polarization) response. The aptamer disclosed by the invention canbe specifically bound to immune globulin E (IgE) so as to produce an obvious fluorescence anisotropy (fluorescence polarization) signal change. A fluorescent dye fluorescein or tetramethyl rhodamineis modified to base sites of specific nucleotides of the aptamer of the IgE, so that the obtained fluorescent dye labeling aptamer maintains high affinity and is capable of producing sensitive signalresponse to the IgE. The aptamer labeled by the fluorescent dyes is capable of sensitively and rapidly detecting the IgE. The fluorescence anisotropy (fluorescence polarization) detection method is simple in operation and excellent in reproducibility.

The invention provides a test strip for screening specific fruits allergens IgE (Immunoglobulin E). The test strip is coated with a fruits antigen marked by colloidal gold. The test strip utilizes a colloidal gold marking technology; firstly, the colloidal gold mark is used for marking the specific fruits allergens; then the marked allergens are uniformly sprayed on a cellulose acetate membrane or a nitrocellulose membrane to prepare a test strip product to carry out allergen detection; the test strip is simple and convenient to operate, accurate in result and low in cost and can realize multi-term free detection.

Embodiments of the invention provide shaped masses (SM) comprising one or more drugs such as proteins or polypeptides and methods for forming and delivering such SM's. One embodiment provides a SM comprising a drug e.g., a protein or polypeptide having a biological activity in the body of a mammal. The SM is formed by compression of a precursor material (PM) comprising the drug wherein an amount of biologically active drug in the SM is a minimum level to that in the PM. Drugs which may be incorporated into the SM include insulin, incretins and immunoglobulins e.g., interleukin neutralizing antibodies or TNF-α-inhibiting antibodies. Embodiments of the invention are particularly useful for the oral delivery of drugs which would be degraded within the GI tract, wherein the SM containing the drug is formed as or incorporated into a tissue penetrating member which is inserted into the intestinal wall after oral ingestion.